Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant HSV-tk adenoviral gene therapy before radical prostatectomy
NL-OMON21955Phase 1Active, not recruiting
- Sponsor
- Erasmus MC Revolving Fund
- Start
- Feb 2001
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of adenoviral HSV-tk gene therapy and ganciclovir in prostate cancer (PCa), sponsored by Erasmus MC Revolving Fund. Primary endpoints: Safety and toxicity of adenovirus-mediated thymidine kinase gene therapy and Laboratory safety assessments. Started Feb 2001; status: active, not recruiting.
02
Drugs
adenoviral HSV-tk gene therapyganciclovir
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON21955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21955.